vonoprazan
Trade name: Voquezna
Approved
May 3, 2022
Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori. — Wikipedia
Clinical trial activity
129 trials · 79 clinical orgs · 1 marketing orgs
Earliest trial started Sep 1, 2007 (NCT02123927)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
2020s
- May 3, 2022
Phathom Pharmaceuticals, Inc. — Earliest FDA Approval
- May 3, 2022
Phathom Pharmaceuticals, Inc. — NDA Secondary Org
- May 3, 2022
Phathom Pharmaceuticals, Inc. — NDA Organization
- Jul 17, 2024
Phathom Pharmaceuticals, Inc. — Marketing Organization
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 4
- Adolescent · Phase 3
- Bacterial Infections · Phase 4
- Drugs, Investigational · Phase 1
- Drug Therapy · Phase 4
- Duodenal Ulcer · Phase 3
- Eosinophilic Esophagitis · Phase 2
- Esophageal and Gastric Varices · Phase 3
- Esophagitis · Phase 4
- Esophagitis, Peptic · Phase 4
- Fasting · Phase 1
- Gastritis · Phase 4
- Gastroesophageal Reflux · Phase 4
- Healthy Volunteers · Phase 3
- Heartburn · Phase 3
- Helicobacter Infections · Phase 4
- Helicobacter pylori · Phase 4
- Hemorrhage · Phase 4
- Hypertension, Portal · Phase 3
- Infections · Phase 4
- Intestinal Neoplasms · Phase 4
- Peptic Ulcer · Phase 3
- Proton Pump Inhibitors · Phase 4
- Stomach Ulcer · Phase 4
- Treatment Outcome · Phase 3
Mechanism of action
HCN1 antagonist
- Potassium-transporting ATPaseINHIBITOR
Potassium-transporting ATPase inhibitor
Inhibits human muscarine M1, M2, and M3 receptors, rat L-type calcium channel, rat sodium channel, rat serotonin 5-HT2 receptor, and guinea-pig sigma receptor by ≥50% but at concentrations higher than the Cmax.
Combination products
voquezna dual pak
with amoxicillin
voquezna triple pak
with amoxicillin, clarithromycin
Also known as vonoprazan, amoxicillin, and clarithromycin, vonoprazan+amoxicillin+clarithromycin 14 days, vonoprazan+amoxicillin+clarithromycin 7 days
Approval history
- approvedPriority reviewFast trackMay 3, 2022
Chemistry & pharmacology
SMILES
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1.O=C(O)/C=C/C(=O)O- Mol. weight
- 461.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaVonoprazan ↗
- ChEMBLCHEMBL2079130 ↗
- ChEMBLCHEMBL2064032 ↗
Also known as
- 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine
- tak438
- tak 438
- tak-438
- tak-438
- tak-438
- tak-438
- takecab
- vonoprazan
- vonoprazan
- vonoprazan
- vonoprazan
- vonoprazan
- vonoprazan
- vonoprazan
- vonoprazan fumarate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07293910 | Phase 2 | Dec 20, 2025 | Tanta University |
| NCT07267260 | Phase 2 | Dec 16, 2025 | King Edward Medical University |
| NCT07275632 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2025 | Chongqing Medical University, Sun Yat-Sen University |
| NCT07278349 | Phase 1 | Sep 21, 2025 | Humanis Saglık Anonim Sirketi |
| NCT07179159 | N/A | Sep 9, 2025 | Qilu Hospital of Shandong University, Shandong University, Shandong University of Traditional Chinese Medicine, Zibo Maternal and Child Health Hospital |
| NCT07159412 | N/A | Aug 31, 2025 | Nanjing Medical University |
| NCT07130253 | N/A | Aug 18, 2025 | National Taiwan University |
| NCT07040839 | Phase 4 | Jul 31, 2025 | Rehman Medical Institute - RMI |
| NCT06953986 | N/A | Jun 7, 2025 | Asian Institute of Gastroenterology |
| NCT06901375 | Early Phase 1 (Phase 1) | May 31, 2025 | Nanjing Medical University |
| NCT07045688 | N/A | May 13, 2025 | Sohag University |
| NCT06955520 | N/A | Apr 30, 2025 | Asian Institute of Gastroenterology |
| NCT06929962 | Phase 4 | Apr 24, 2025 | Nanjing Medical University |
| NCT07306988 | Phase 4 | Apr 17, 2025 | Nanjing Medical University |
| NCT07068607 | Phase 4 | Apr 1, 2025 | People's Liberation Army of China |
| NCT06851559 | Phase 2 | Mar 31, 2025 | Phathom Pharmaceuticals, Inc. |
| NCT06959368 | Phase 4 | Mar 25, 2025 | Asian Institute of Gastroenterology |
| NCT06783257 | Phase 2 | Feb 28, 2025 | Shandong New Time Pharmaceutical Co., LTD |
| NCT07242456 | Phase 2/Phase 3 (Phase 3) | Feb 17, 2025 | First People's Hospital of Hangzhou |
| NCT06831344 | Phase 1 | Feb 14, 2025 | Phathom Pharmaceuticals, Inc. |
Organizations
Research & Development (79)
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | For profit | MKTG | Jul 17, 2024 |
| Phathom Pharmaceuticals, Inc. | For profit | NDA2 | May 3, 2022 |
| Phathom Pharmaceuticals, Inc. | For profit | NDA | May 3, 2022 |